TYRO3：癌症治疗的潜在靶点。
TYRO3: A potential therapeutic target in cancer.
机构信息
1 Department of Physiology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
2 College of Medicine, University of Illinois, IL 60612, USA.
出版信息
Exp Biol Med (Maywood). 2019 Feb;244(2):83-99. doi: 10.1177/1535370219828195. Epub 2019 Feb 2.
Abstract
Cancer is among the leading causes of death worldwide. In 2016, 8.9 million people are estimated to have died from various forms of cancer. The current treatments, including surgery with chemotherapy and/or radiation therapy, are not effective enough to provide full protection from cancer, which highlights the need for developing novel therapy strategies. In this review, we summarize the molecular biology of a unique member of a subfamily of receptor tyrosine kinase, TYRO3 and discuss the new insights in TYRO3-targeted treatment for cancer therapy.
摘要
癌症是全球主要死因之一。2016 年，估计有 890 万人死于各种形式的癌症。目前的治疗方法，包括手术结合化疗和/或放射治疗，不足以提供对癌症的充分保护，这突出了开发新的治疗策略的必要性。在这篇综述中，我们总结了受体酪氨酸激酶亚家族中一个独特成员 TYRO3 的分子生物学，并讨论了针对 TYRO3 的治疗方法在癌症治疗中的新见解。
相似文献
1
TYRO3: A potential therapeutic target in cancer.TYRO3：癌症治疗的潜在靶点。
Exp Biol Med (Maywood). 2019 Feb;244(2):83-99. doi: 10.1177/1535370219828195. Epub 2019 Feb 2.
2
Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression.酪氨酸蛋白激酶受体 Tyro3 的过表达及其对肝细胞癌进展的影响。
Int J Oncol. 2016 Jan;48(1):358-66. doi: 10.3892/ijo.2015.3244. Epub 2015 Nov 13.
3
[ALK inhibitor].[ALK抑制剂]
Nihon Yakurigaku Zasshi. 2013 Jul;142(1):48-50. doi: 10.1254/fpj.142.48.
4
Tyrosine kinases as targets in cancer therapy - successes and failures.酪氨酸激酶作为癌症治疗靶点——成功与失败
Expert Opin Ther Targets. 2003 Apr;7(2):215-34. doi: 10.1517/14728222.7.2.215.
5
Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.酪氨酸激酶TAM亚家族抑制剂：合成与生物学评价。
Eur J Med Chem. 2013 Mar;61:2-25. doi: 10.1016/j.ejmech.2012.06.005. Epub 2012 Jun 12.
6
Receptor Tyrosine Kinase-Targeted Cancer Therapy.受体酪氨酸激酶靶向癌症治疗。
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.
7
State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.TAM 家族小分子抑制剂的最新进展：化学家的观点。
Eur J Med Chem. 2015 Nov 13;105:220-37. doi: 10.1016/j.ejmech.2015.10.003. Epub 2015 Oct 22.
8
Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.酪氨酸蛋白激酶受体Tyro3的过表达导致卵巢癌细胞获得紫杉醇耐药性。
Mol Med Rep. 2015 Jul;12(1):1485-92. doi: 10.3892/mmr.2015.3542. Epub 2015 Mar 24.
9
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.一个 microRNA-7/生长停滞特异性 6/TYRO3 轴调节人肝癌索拉非尼耐药细胞的生长和侵袭。
Hepatology. 2018 Jan;67(1):216-231. doi: 10.1002/hep.29478. Epub 2017 Nov 29.
10
Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.Tyr3 介导的 ACTN4 酪氨酸磷酸化是 FAK 依赖性的，降低了对 m-Calpain 切割的敏感性。
Int J Biochem Cell Biol. 2018 Feb;95:73-84. doi: 10.1016/j.biocel.2017.12.014. Epub 2017 Dec 20.
引用本文的文献
1
Recent advances in TAM mechanisms in lung diseases.肺部疾病中肿瘤相关巨噬细胞（TAM）机制的最新进展。
J Transl Med. 2025 Apr 26;23(1):479. doi: 10.1186/s12967-025-06398-2.
2
Navigating TAM receptor dynamics in tumour immunotherapy.探索肿瘤免疫治疗中的TAM受体动力学
Cancer Immunol Immunother. 2025 Mar 15;74(5):146. doi: 10.1007/s00262-024-03879-z.
3
AXL signaling in cancer: from molecular insights to targeted therapies.癌症中的AXL信号传导：从分子洞察到靶向治疗。
Signal Transduct Target Ther. 2025 Feb 10;10(1):37. doi: 10.1038/s41392-024-02121-7.
4
Analysis of the Plasticity of Circulating Tumor Cells Reveals Differentially Regulated Kinases During the Suspension-to-Adherent Transition.循环肿瘤细胞可塑性分析揭示了悬浮至贴壁转化过程中差异调节的激酶。
Cancer Med. 2024 Oct;13(20):e70339. doi: 10.1002/cam4.70339.
5
RREB1 regulates neuronal proteostasis and the microtubule network.RREB1 调节神经元的蛋白质平衡和微管网络。
Sci Adv. 2024 Jan 12;10(2):eadh3929. doi: 10.1126/sciadv.adh3929. Epub 2024 Jan 10.
6
Therapeutic targeting of the functionally elusive TAM receptor family.靶向功能隐匿的 TAM 受体家族的治疗方法。
Nat Rev Drug Discov. 2024 Mar;23(3):201-217. doi: 10.1038/s41573-023-00846-8. Epub 2023 Dec 13.
7
TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process.TYRO3 通过增强上皮-间充质转化过程促进结直肠癌的肿瘤发生和耐药性。
Aging (Albany NY). 2023 Apr 14;15(8):3035-3051. doi: 10.18632/aging.204656.
8
Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.靶向 BRD3 可消除核 TYRO3 诱导的结直肠癌转移。
Sci Adv. 2023 Apr 14;9(15):eade3422. doi: 10.1126/sciadv.ade3422. Epub 2023 Apr 12.
9
Follicular Thyroid Adenoma and Follicular Thyroid Carcinoma-A Common or Distinct Background? Loss of Heterozygosity in Comprehensive Microarray Study.滤泡性甲状腺腺瘤与滤泡性甲状腺癌——共同背景还是不同背景？综合微阵列研究中的杂合性缺失
Cancers (Basel). 2023 Jan 19;15(3):638. doi: 10.3390/cancers15030638.
10
G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models.G-749促进受体酪氨酸激酶TYRO3降解并在结肠癌细胞系和异种移植小鼠模型中诱导细胞凋亡。
Front Pharmacol. 2021 Oct 14;12:730241. doi: 10.3389/fphar.2021.730241. eCollection 2021.
本文引用的文献
1
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models.西他拉替尼增强了难治性癌症模型中的免疫检查点阻断作用。
JCI Insight. 2018 Nov 2;3(21):124184. doi: 10.1172/jci.insight.124184.
2
Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.通过单个甲基实现高度选择性 MERTK 抑制剂。
J Med Chem. 2018 Nov 21;61(22):10242-10254. doi: 10.1021/acs.jmedchem.8b01229. Epub 2018 Nov 5.
3
MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression.MicroRNA-7 通过抑制 TYRO3 和磷酸肌醇 3-激酶/蛋白激酶 B/雷帕霉素靶蛋白通路抑制结直肠癌细胞的增殖、迁移和侵袭。
Int J Mol Med. 2018 Nov;42(5):2503-2514. doi: 10.3892/ijmm.2018.3864. Epub 2018 Sep 7.
4
The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.原癌基因 Mer 酪氨酸激酶是套细胞淋巴瘤的一个新的治疗靶点。
J Hematol Oncol. 2018 Mar 20;11(1):43. doi: 10.1186/s13045-018-0584-6.
5
Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology.靶向 Tyro3 通过 tau 介导的突触病变改善 PGRN 突变 FTLD-TDP 的模型。
Nat Commun. 2018 Jan 30;9(1):433. doi: 10.1038/s41467-018-02821-z.
6
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.RXDX-106对MerTK激活的胃癌细胞系中MerTK的抑制作用。
Oncotarget. 2017 Nov 11;8(62):105727-105734. doi: 10.18632/oncotarget.22394. eCollection 2017 Dec 1.
7
Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.Tyr3 介导的 ACTN4 酪氨酸磷酸化是 FAK 依赖性的，降低了对 m-Calpain 切割的敏感性。
Int J Biochem Cell Biol. 2018 Feb;95:73-84. doi: 10.1016/j.biocel.2017.12.014. Epub 2017 Dec 20.
8
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.TYRO3和AXL作为平滑肌肉瘤潜在治疗靶点的表达及作用
Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12.
9
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.一个 microRNA-7/生长停滞特异性 6/TYRO3 轴调节人肝癌索拉非尼耐药细胞的生长和侵袭。
Hepatology. 2018 Jan;67(1):216-231. doi: 10.1002/hep.29478. Epub 2017 Nov 29.
10
TAM Receptor Tyrosine Kinases in Cancer Drug Resistance.TAM 受体酪氨酸激酶在癌症耐药中的作用。
Cancer Res. 2017 Jun 1;77(11):2775-2778. doi: 10.1158/0008-5472.CAN-16-2675. Epub 2017 May 19.
Zotero 插件